Could a Gut-Focused drug revive immunotherapy for tough melanomas?
NCT ID NCT07631325
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding axelopran, a drug that blocks opioid side effects in the gut, to the immunotherapy nivolumab can help people with advanced melanoma that no longer responds to PD-1 inhibitors. The trial includes about 28 adults with unresectable or metastatic cutaneous melanoma. Researchers will monitor safety, tumor response, and immune system changes to see if this combination offers a new path forward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axelopran and nivolumab
What this could lead to
If successful, this combination could offer a new treatment option for people with melanoma that no longer responds to standard immunotherapy.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply broadly. The drug combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact